Oventus Medical Ltd (ASX: OVN) is pleased to announce the Canadian launch of the O2Vent® Optima device which treats both the potentially fatal condition, obstructive sleep apnoea (OSA) and snoring. The device launch in Canada follows the successful completion of a controlled market release, with early results demonstrating strong patient acceptance. The O2Vent® Optima is the newest product in the O2Vent® oral device range within Oventus’ Sleep Treatment Platform. Its Canadian launch follows the news in January this year, that the O2Vent® Optima had been launched in the Australian market.
For more information, download the attached PDF.
Download this document
